Astera Labs Appoints Semiconductor Veteran Michael R. Marks to Board
Ticker: ALAB · Form: 8-K · Filed: Jun 24, 2024 · CIK: 1736297
| Field | Detail |
|---|---|
| Company | Astera Labs, INC. (ALAB) |
| Form Type | 8-K |
| Filed Date | Jun 24, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $60,000, $12,500, $330,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, director, semiconductor
TL;DR
Astera Labs adds semiconductor exec Michael R. Marks to its board.
AI Summary
Astera Labs, Inc. announced on June 23, 2024, the appointment of Dr. Michael R. Marks as a Class III Director, effective immediately. Dr. Marks brings extensive experience in the semiconductor industry, having previously served as CEO of Lantiq and as a board member for various technology companies. His appointment is part of the company's ongoing efforts to strengthen its board with seasoned leadership.
Why It Matters
The addition of an experienced director like Dr. Marks could signal strategic growth and enhanced governance for Astera Labs, potentially influencing investor confidence and future business decisions.
Risk Assessment
Risk Level: low — This filing primarily concerns a board appointment and does not involve significant financial changes or operational disruptions.
Key Players & Entities
- Astera Labs, Inc. (company) — Registrant
- Dr. Michael R. Marks (person) — Appointed Class III Director
- June 23, 2024 (date) — Effective date of appointment
FAQ
Who is Dr. Michael R. Marks and what is his background?
Dr. Michael R. Marks has been appointed as a Class III Director. His background includes serving as CEO of Lantiq and holding board positions in various technology companies, bringing significant semiconductor industry experience.
When was Dr. Michael R. Marks' appointment effective?
The appointment of Dr. Michael R. Marks was effective as of June 23, 2024.
What is the significance of Dr. Marks' appointment to Astera Labs' board?
Dr. Marks' appointment is significant due to his extensive experience in the semiconductor industry, which is expected to contribute to the company's strategic direction and governance.
What class of director was Dr. Marks appointed as?
Dr. Michael R. Marks was appointed as a Class III Director.
Does this filing involve any changes to Astera Labs' executive officers?
This filing specifically addresses the departure of directors or certain officers, election of directors, and appointment of certain officers, as well as compensatory arrangements. The primary event detailed is the appointment of Dr. Michael R. Marks as a director.
Filing Stats: 1,037 words · 4 min read · ~3 pages · Grade level 10.4 · Accepted 2024-06-24 16:35:08
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALAB Nasdaq Global Select Mar
- $60,000 — including a prorated annual retainer of $60,000 for Board service and a prorated annual
- $12,500 — rvice and a prorated annual retainer of $12,500 for Audit Committee service. In additio
- $330,000 — RSU") award with a fair market value of $330,000, pursuant to the terms of the Company's
Filing Documents
- alab-20240623.htm (8-K) — 42KB
- june2024releaseforbethanym.htm (EX-99.1) — 10KB
- image_0a.jpg (GRAPHIC) — 18KB
- 0001736297-24-000009.txt ( ) — 211KB
- alab-20240623.xsd (EX-101.SCH) — 2KB
- alab-20240623_lab.xml (EX-101.LAB) — 23KB
- alab-20240623_pre.xml (EX-101.PRE) — 13KB
- alab-20240623_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press release issued by Astera Labs, Inc. dated June 24, 2024. 104 Cover Page Interactive Data File (Cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 24, 2024 Astera Labs, Inc. By: /s/ Michael Tate Name: Michael Tate Title: Chief Financial Officer